Photo of Ann Mullally, MD

Ann Mullally, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-4980


amullally@partners.org

Photo of Ann Mullally, MD

Brigham And Women's Hospital
Phone: (617) 525-4980


amullally@partners.org

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Ann Mullally, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Ann Mullally, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Attending Physician , Leukemia Program, Medical Oncology, Dana-Farber Cancer Institute
  • Associate Physician, Hematology, Brigham And Women's Hospital

Research Abstract

I am a translational cancer researcher in the field of myeloid malignancies, with a focus on myeloproliferative neoplasms (MPN). My laboratory studies the biology, genetics, and therapy of myeloid cancers using primary human samples, murine models and multiple in vitro model systems. We use standard biochemical assays, proteomics, multi-parameter flow cytometry, in vivo functional genomics (including CRISPR) and next generation sequencing technologies. Current projects in my laboratory are focused on the biology of mutant calreticulin in MPN, hematopoietic-stromal interactions in the context of myelofibrosis, , the differential molecular dependencies of disease-propagating stem cells in myeloid cancers, identification of heritability alleles for familial MPN. My laboratory is actively expanding currently so please contact me if you are an exceptionally motivated post-doctoral candidate interested in joining my group.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Kramer F, Mullally A. Antibody targeting of mutant calreticulin in myeloproliferative neoplasms. J Cell Mol Med 2023. PubMed
  • How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPN. Blood 2022. PubMed
  • Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A. CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response. Leukemia 2022. PubMed
  • Rolles B, Mullally A. Molecular Pathogenesis of Myeloproliferative Neoplasms. Curr Hematol Malig Rep 2022. PubMed
  • Vining KH, Marneth AE, Adu-Berchie K, Grolman JM, Tringides CM, Liu Y, Wong WJ, Pozdnyakova O, Severgnini M, Stafford A, Duda GN, Hodi FS, Mullally A, Wucherpfennig KW, Mooney DJ. Mechanical checkpoint regulates monocyte differentiation in fibrotic niches. Nat Mater 2022; 21:939-950. PubMed
  • Jutzi JS, Marneth AE, Ciboddo M, Guerra-Moreno A, Jiménez-Santos MJ, Kosmidou A, Dressman JW, Liang H, Hamel RSL, Lozano PR, Rumi E, Doench J, Gotlib JR, Krishnan A, Elf S, Al-Shahrour F, Mullally A. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPN. Blood 2022. PubMed
  • Gigoux M, Holmström MO, Zappasodi R, Park JJ, Pourpe S, Bozkus CC, Mangarin LMB, Redmond D, Verma S, Schad S, George MM, Venkatesh D, Ghosh A, Hoyos D, Molvi Z, Kamaz B, Marneth AE, Duke W, Leventhal MJ, Jan M, Ho VT, Hobbs GS, Knudsen TA, Skov V, Kjær L, Larsen TS, Hansen DL, Lindsley RC, Hasselbalch H, Grauslund JH, Lisle TL, Met Ö, Wilkinson P, Greenbaum B, Sepulveda MA, Chan T, Rampal R, Andersen MH, Abdel-Wahab O, Bhardwaj N, Wolchok JD, Mullally A, Merghoub T. Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Sci Transl Med 2022; 14:eaba4380. PubMed
  • Van Egeren D, Kamaz B, Liu S, Nguyen M, Reilly CR, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Michor F, Cortes-Ciriano I, Mullally A, Hormoz S. Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol 2022; 107:14-19. PubMed
  • Takei H, Coelho-Silva JL, Tavares Leal C, Queiroz Arantes Rocha A, Mantello Bianco T, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima K, Machado-Neto JA, Kobayashi SS, Lobo de Figueiredo-Pontes L. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Sci 2022; 113:597-608. PubMed
  • Knudsen TA, Skov V, Stevenson KE, Werner L, Duke W, Laurore C, Gibson CJ, Nag A, Thorner AR, Wollison B, Hansen DL, Ellervik C, El Fassi D, de Stricker K, Ocias LF, Brabrand M, Bjerrum OW, Overgaard U, Frederiksen M, Kristensen T, Kruse T, Thomassen M, Mourits-Andersen T, Severinsen MT, Stentoft J, Starklint J, Neuberg D, Kjaer L, Larsen TS, Hasselbalch HC, Lindsley RC, Mullally A. Genomic Profiling of a Randomized Trial of Interferon-α versus Hydroxyurea in MPN Reveals Mutation-Specific Responses. Blood Adv 2021. PubMed
  • Contreras Castillo S, Montibus B, Rocha A, Duke W, von Meyenn F, McLornan D, Harrison C, Mullally A, Schulz R, Oakey RJ. Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. Genome Res 2021; 31:1381-1394. PubMed
  • Rivera JF, Baral AJ, Nadat F, Boyd G, Smyth R, Patel H, Burman EL, Alameer G, Boxall SA, Jackson BR, Baxter EJ, Laslo P, Green AR, Kent DG, Mullally A, Chen E. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood Adv 2021; 5:1922-1932. PubMed
  • Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, Kamaz B, Kalyva M, DeAngelo DJ, Galinsky I, Wadleigh M, Winer ES, Luskin MR, Stone RM, Garcia JS, Hobbs GS, Camargo FD, Michor F, Mullally A, Cortes-Ciriano I, Hormoz S. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell 2021. PubMed
  • Kamaz B, Mullally A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia 2021; 35:279-281. PubMed
  • Ng J, Guo F, Marneth AE, Ghanta S, Kwon MY, Keegan J, Liu X, Wright KT, Kamaz B, Cahill LA, Mullally A, Perrella MA, Lederer JA. Augmenting emergency granulopoiesis with CpG conditioned mesenchymal stromal cells in murine neutropenic sepsis. Blood Adv 2020; 4:4965-4979. PubMed
  • Jacquelin S, Kramer F, Mullally A, Lane SW. Murine Models of Myelofibrosis. Cancers (Basel) 2020. PubMed
  • Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv 2020; 4:1792-1800. PubMed
  • Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 2020; 588:157-163. PubMed
  • How J, Leiva O, Bogue T, Fell GG, Bustoros MW, Connell NT, Connors JM, Ghobrial IM, Kuter DJ, Mullally A, Neuberg D, Zwicker JI, Fogerty AE, Hobbs GS. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res 2020; 98:106459. PubMed
  • Jutzi JS, Mullally A. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN. 2020; 11:2093. PubMed
  • Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia 2019. PubMed
  • How J, Hobbs G, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood 2019. PubMed
  • Marneth AE, Mullally A. The Molecular Genetics of Myeloproliferative Neoplasms. Cold Spring Harb Perspect Med 2019. PubMed
  • Liu S, Marneth AE, Alexe G, Walker SR, Gandler HI, Ye DQ, Labella K, Mathur R, Toniolo PA, Tillgren M, Gokhale PC, Barbie D, Mullally A, Stegmaier K, Frank DA. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. Blood Adv 2018; 2:3428-3442. PubMed
  • Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 2018. PubMed
  • Abdelfattah NS, Mullally A. Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells. 2018. PubMed
  • Ciboddo M, Mullally A. JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program 2018; 2018:110-117. PubMed
  • Elf S, Abdelfattah NS, Baral AJ, Beeson D, Rivera JF, Ko A, Florescu N, Birrane G, Chen E, Mullally A. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood 2017. PubMed
  • Mullally A. Kinase Inhibitors in the Treatment of Myeloid Malignancies. Hematol Oncol Clin North Am 2017; 31:ix-x. PubMed
  • Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2017; 31:613-626. PubMed
  • Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R. Gli1(+) Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell 2017; 20:785-800.e8. PubMed
  • Mead AJ, Mullally A. Myeloproliferative Neoplasm Stem Cells. Blood 2017. PubMed
  • Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell 2016; 30:404-417. PubMed
  • Elf S, Abdelfattah NS, Chen E, Perales-Paton J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. 2016. PubMed
  • Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Rep 2015; 13:2345-52. PubMed
  • Jeremy Wen Q, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD. Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med 2015; 21:1473-80. PubMed
  • Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. British Journal of Haematology 2015. PubMed
  • Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T. Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology. Haematologica 2015. PubMed
  • Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015; 125:1548-52. PubMed
  • Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H. Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice. Blood 2015; 125:1014-24. PubMed
  • Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood 2015. PubMed
  • Chen E, Mullally A. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? Hematology Am Soc Hematol Educ Program 2014; 2014:268-76. PubMed
  • Lane SW, Mullally A. Hit the spleen, JAK! Blood 2014; 124:2898-900. PubMed
  • Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. Proc Natl Acad Sci U S A 2014; 111:15190-5. PubMed
  • Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 2014; 26:509-20. PubMed
  • Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med 2014; 211:605-12. PubMed
  • De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA. Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS ONE 2014; 9:e96209. PubMed
  • Mullally A, Ebert BL. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML. Cell Stem Cell 2013; 13:257-8. PubMed
  • Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood 2013; 121:3692-702. PubMed
  • Mullally A, Ebert BL. Janus reveals another face: the biologic rationale for targeting Janus kinase 2 in lymphoma. J Clin Oncol 2012; 30:4168-70. PubMed
  • Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. Hematol Oncol Clin North Am 2012; 26:1065-81. PubMed
  • Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489:155-9. PubMed
  • Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood 2012; 120:166-72. PubMed
  • Mullally A, Ebert BL. STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation. Cancer Cell 2010; 18:405-6. PubMed
  • Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol 2010; 28:e409-11. PubMed
  • Mullally A, Ebert BL. NF1 inactivation revs up Ras in adult acute myelogenous leukemia. Clin Cancer Res 2010; 16:4074-6. PubMed
  • Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17:584-96. PubMed
  • Abdel-Wahab O,Mullally A,Hedvat C,Garcia-Manero G,Patel J,Wadleigh M,Malinge S,Yao J,Kilpivaara O,Bhat R,Huberman K,Thomas S,Dolgalev I,Heguy A,Paietta E,Le Beau MM,Beran M,Tallman MS,Ebert BL,Kantarjian HM,Stone RM,Gilliland DG,Crispino JD,Levine RL. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114:144-7. PubMed
  • Kilpivaara O,Mukherjee S,Schram AM,Wadleigh M,Mullally A,Ebert BL,Bass A,Marubayashi S,Heguy A,Garcia-Manero G,Kantarjian H,Offit K,Stone RM,Gilliland DG,Klein RJ,Levine RL. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 2009; 41:455-9. PubMed
  • Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:1355-62. PubMed
  • Mullally AM, Vogelsang GB, Moliterno AR. Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev. 2004; 18:227-34. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Ann Mullally, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members